These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26148595)

  • 1. Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.
    Liu H; Wang Y; Li G; Song W; Wang R
    J Cancer Res Ther; 2015; 11(2):331-5. PubMed ID: 26148595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.
    Yang ZH; Ren J; Yi LJ; Zheng JH; Wei H
    Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3391-6. PubMed ID: 26439033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer.
    Li J; Yin J; Zhu X; Liu Y; Cao J; Lu F; Zuo Y
    Anticancer Drugs; 2008 Aug; 19(7):745-8. PubMed ID: 18594218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicenter Feasibility Study with S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients with Untreated Metastatic Colorectal Cancer: The Result of Final Analysis.
    Lu M; Wang Y; Liu W; Bai C; Xu J; Shen L
    Hepatogastroenterology; 2014 Jun; 61(132):1018-23. PubMed ID: 26158159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer.
    Wang ZQ; Zhang DS; Xu N; Luo DY; Deng YH; Wang FH; Luo HY; Qiu MZ; Li YH; Xu RH
    Chin J Cancer; 2016 Jan; 35():8. PubMed ID: 26739998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
    Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
    Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
    Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.
    Hong J; Han SW; Ham HS; Kim TY; Choi IS; Kim BS; Oh DY; Im SA; Kang GH; Bang YJ; Kim TY
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1323-31. PubMed ID: 20734048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Report of Phase II Study on Bi-weekly SOX plus Cetuximab Treatment for Wild-type K-RAS Advanced and Recurrent Colorectal Cancer.
    Ogawa M; Anan T; Suzuki T; Okuma M; Ichihara K; Hasegawa T; Yoshida K; Yanaga K
    Anticancer Res; 2016 May; 36(5):2505-11. PubMed ID: 27127165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
    Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
    Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
    Yamazaki K; Kuwano H; Ojima H; Otsuji T; Kato T; Shimada K; Hyodo I; Nishina T; Shirao K; Esaki T; Ohishi T; Denda T; Takeuchi M; Boku N
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):569-77. PubMed ID: 25575764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
    Zang DY; Lee BH; Park HC; Song HH; Kim HJ; Jung JY; Kim JH; Kim HY; Kwon JH; Hwang SW; Park SR; Park CH; Kim KO; Kim MJ; Jang KM
    Ann Oncol; 2009 May; 20(5):892-6. PubMed ID: 19153122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
    Tokunaga Y; Sasaki H; Matsueda S
    Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
    Moehler M; Mahlberg R; Heinemann V; Obermannová R; Kubala E; Melichar B; Weinmann A; Scigalla P; Tesařová M; Janda P; Hédouin-Biville F; Mansoor W
    Gastric Cancer; 2017 Mar; 20(2):358-367. PubMed ID: 27255289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
    Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
    Chung KY; Saito K; Zergebel C; Hollywood E; Segal M; Saltz LB
    Oncology; 2011; 81(2):65-72. PubMed ID: 21968463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
    Higashi D; Egawa Y; Hirano Y; Hirano K; Miyake T; Takahashi H; Uwatoko S; Abe S; Yamamoto S; Mikami K; Futami K; Maekawa T; Inoue R; Miyazaki M
    Anticancer Res; 2014 Aug; 34(8):4595-9. PubMed ID: 25075105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of oxaliplatin and tegafur/uracil and oral folinic acid for advanced or metastatic colorectal cancer in elderly patients.
    Rosati G; Cordio S; Tucci A; Blanco G; Bordonaro R; Reggiardo G; Manzione L
    Oncology; 2005; 69(2):122-9. PubMed ID: 16118508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.